The routine use of SDD of aminoglycosides requires robust
evidence that such therapy is no less clinically or microbiologically
effective and no more toxic than is traditional MDD
therapy. Only when such evidence is available can the decreased
costs of administration and drug preparation and the
increased convenience of SDD justify its use